CJC-1295 Endurance Athletes Protocol: Dosing, Timing, and What the Evidence Actually Shows

What CJC-1295 Is and Why Endurance Athletes Use It

CJC-1295 is a 30-amino-acid GHRH analog developed by ConjuChem Biotechnologies. The drug-affinity complex (DAC) version covalently binds circulating albumin through a maleimide linker, stretching its biological half-life from roughly 7 minutes (native GHRH) to approximately 6-8 days. That extended presence at the pituitary produces a sustained rise in growth hormone (GH) pulse amplitude rather than a single sharp spike.

Endurance athletes tolerate and recover from very different stressors than strength athletes. A 100-mile-per-week runner accumulates repetitive connective tissue microtrauma, cytokine-driven inflammation, and chronic cortisol elevation that compress slow-wave sleep. GH is secreted primarily during stages 3 and 4 of non-REM sleep, and blunted GH output has been documented in overtrained athletes. Meeusen et al., 2013, European College of Sport Science / ACSM Joint Consensus Statement on overtraining.

The theoretical rationale for CJC-1295 in endurance sport rests on three pillars: faster connective tissue remodeling via IGF-1-mediated collagen synthesis, accelerated glycogen resynthesis through GH-driven lipolysis (sparing glucose), and subjective improvement in sleep depth that athletes consistently report.

The Pharmacology Behind the Extended Half-Life

Native GHRH1-29 amide (sermorelin) is cleared by dipeptidyl peptidase IV and neutral endopeptidase within minutes of injection. CJC-1295 adds a Lys-linker at position 29 and substitutes four amino acids to resist proteolysis. When the DAC moiety attaches to albumin (serum half-life approximately 19 days), the peptide recirculates as a reservoir, releasing active GHRH slowly. Jetté et al., 2005, Journal of Clinical Endocrinology and Metabolism.

How GH Supports Endurance-Sport Physiology

GH does not directly build contractile muscle in the way testosterone does. Its main endurance-relevant actions include stimulating hepatic and peripheral IGF-1 production, promoting free fatty acid mobilization during submaximal exercise, and supporting collagen synthesis in tendons and cartilage. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that IGF-1 mediates much of GH's anabolic signaling in musculoskeletal tissue. Giustina et al., 2020, JCEM.

The Clinical Trial Evidence: What Has Actually Been Tested

No published RCT has enrolled endurance athletes and randomized them to CJC-1295. The honest categorization of evidence tiers is below.

Phase I/II Trials in Healthy Adults

The Jetté et al. Phase I/II study (N=65 healthy adults) showed that a single 60 mcg/kg dose of CJC-1295 with DAC produced a 2-to-10-fold increase in mean serum GH concentration that persisted for 6 days post-injection, and IGF-1 levels rose 1.5-to-3-fold for 9-11 days. No serious adverse events were reported at doses up to 60 mcg/kg. Jetté et al., 2005, JCEM.

That same paper reported dose-dependent IGF-1 increases across three cohorts (30, 60, and 90 mcg/kg), with the 60 mcg/kg group showing mean IGF-1 elevation of approximately 2.3-fold from baseline at day 7 post-injection. The effect at 90 mcg/kg was not substantially larger, suggesting a plateau in pituitary responsiveness at moderate doses.

GH Replacement Literature: A Proxy for Athletes

Because no athletic trial exists, many practitioners extrapolate from GH-deficiency replacement studies. A Cochrane review of GH treatment in adults with GH deficiency (27 RCTs, N=1,415) found consistent reductions in fat mass, increases in lean mass, and improved exercise capacity, though benefits in already-healthy individuals are attenuated. van Bunderen et al. / Cochrane, 2018. The extrapolation from GH-deficient patients to well-trained athletes is a meaningful logical leap, and clinicians should label it as such.

Sermorelin as a Proxy

Sermorelin (GHRH1-29 amide) shares the same receptor target as CJC-1295. A study by Sigalos and Pastuszak (2018) in Sexual Medicine Reviews summarized the clinical data: sermorelin produced statistically significant increases in IGF-1 and improvements in body composition in men over 50, but direct performance data in athletes remain absent. Sigalos and Pastuszak, 2018, Sexual Medicine Reviews.

Structured Protocol for Endurance Athletes

The protocol below synthesizes the Phase I/II pharmacokinetic data with practitioner-reported dosing frameworks. Every recommendation is labeled by evidence level.

Dosing Parameters

Dose: 300-600 mcg per injection subcutaneously. The Jetté trial used weight-based dosing (60 mcg/kg), which translates to roughly 4,200 mcg for a 70 kg athlete. Clinical practitioners typically use the 300-600 mcg flat-dose range to limit IGF-1 overshoot and reduce cost. Evidence level: Phase I pharmacokinetic extrapolation.

Frequency: Once or twice per week. The approximately 6-8 day half-life means twice-weekly dosing creates cumulative GH elevation; once-weekly dosing stays closer to the natural pulsatile rhythm. Athletes with heavier training loads (greater than 12 hours per week) may prefer twice-weekly dosing during peak build phases.

Route: Subcutaneous injection into the abdomen (2 cm from the navel) or the anterior thigh. Use a 29-to-31 gauge, 0.5-inch needle. Rotate injection sites. Intramuscular injection is not necessary and may increase local irritation.

Reconstitution: Lyophilized powder is reconstituted with bacteriostatic water at a concentration of 1 mg/mL (i.e., 1 mL per 1 mg vial). Store reconstituted peptide refrigerated at 2-8°C and use within 30 days.

Injection Timing for Endurance Athletes

Timing matters more than most protocols acknowledge. GH is secreted in pulses, with the largest pulse occurring 60-90 minutes after sleep onset. Injecting CJC-1295 in the evening (30-60 minutes before bed) may augment this natural nocturnal pulse rather than competing with it. Evidence level: physiological inference from GH secretion studies. Van Cauter et al., 2000, JAMA.

Avoid injecting immediately post-exercise. The acute GH spike from exercise (peaking 15-30 minutes into high-intensity effort) is already at maximum receptor occupancy. Stacking an exogenous GHRH signal on top of a saturated pituitary offers minimal additive benefit and wastes the dose.

On rest days, morning injection is acceptable if evening dosing causes sleep disruption (a reported side effect in a minority of users due to vivid dreaming).

Cycle Length and Off-Period

Typical practitioner-advised cycle: 12-16 weeks on, followed by 4-8 weeks off. The rationale is pituitary receptor desensitization. Sustained GHRH receptor activation without an off-period may blunt endogenous GHRH pulsatility over time. No long-term RCT has confirmed the exact duration at which desensitization becomes clinically meaningful in healthy adults, so the 12-16 week recommendation is precautionary and consensus-based.

Athletes commonly align cycles with their competitive calendar: start the cycle 12-16 weeks before the target event (a spring marathon or an Ironman), conclude 4-8 weeks out to allow hormonal normalization before race day.

Stacking With Ipamorelin: The Most Common Endurance Combination

Most practitioners pair CJC-1295 with ipamorelin rather than using CJC-1295 alone.

Why the Combination Is Used

CJC-1295 stimulates GHRH receptors at the pituitary; ipamorelin is a selective ghrelin receptor agonist (GHSR-1a) that independently triggers GH release via a different receptor pathway. Used together, the two peptides produce synergistic GH pulse amplitude without meaningfully increasing cortisol or prolactin, which are side effects common with older GH secretagogues like GHRP-6. Evidence level: in vitro and small clinical series.

Ipamorelin dose in this combination: 100-300 mcg subcutaneously, co-administered with CJC-1295 at the same injection site or in a separate injection. Raun et al., 1998, European Journal of Endocrinology.

Trade-offs of Adding Ipamorelin

Adding ipamorelin increases the total cost and the number of variables to manage. Athletes new to peptide therapy should consider running CJC-1295 alone for 8 weeks before adding ipamorelin, so baseline IGF-1 response can be assessed independently.

Monitoring Labs: What to Check and When

Running CJC-1295 without lab monitoring is clinically inappropriate. The primary risk is IGF-1 overshoot. Chronically supraphysiologic IGF-1 has been associated with increased colorectal and prostate cancer risk in epidemiological cohorts, though no causal relationship has been established for therapeutic GH secretagogue use. Renehan et al., 2004, Lancet.

Baseline Labs (Before Starting)

• IGF-1 (serum): Reference range is age-and-sex-specific. For men 30-40 years old, the normal range is approximately 115-355 ng/mL; for women in the same age bracket, approximately 92-246 ng/mL. Endocrine Society IGF-1 reference data.
• Fasting glucose and HbA1c: GH is counter-regulatory to insulin. Elevated GH can reduce insulin sensitivity, which is relevant for endurance athletes managing carbohydrate periodization.
• Morning cortisol (8 AM serum): Identifies athletes with already-dysregulated HPA axis before adding a GH-axis intervention.
• Lipid panel: Baseline documentation for longitudinal monitoring.
• Thyroid panel (TSH, free T4): GH axis and thyroid axis interact; hypothyroidism blunts GH response.

Mid-Cycle Labs (Week 6-8)

Recheck IGF-1. Target: keep IGF-1 in the upper quartile of the age-sex-matched normal range, not above the upper limit. If IGF-1 exceeds the upper limit of normal, reduce dose by 100-200 mcg per injection and recheck in 4 weeks.

Recheck fasting glucose. A rise greater than 15-20 mg/dL from baseline warrants a dose reduction and endocrinology referral.

End-of-Cycle Labs (Week 12-16)

Full repeat of baseline panel. Compare IGF-1 to pre-cycle value to document response and to ensure normalization before starting an off-period.

Expected Timeline of Outcomes

Athletes consistently ask how quickly CJC-1295 works. The honest answer varies by outcome.

Sleep Quality (Weeks 1-3)

Subjective sleep depth improvement is the earliest and most consistently reported effect. Athletes describe this as "heavier" sleep and more vivid dreams during REM rebound. This is likely a real GH-mediated increase in slow-wave sleep architecture; GH secretion and slow-wave sleep are tightly coupled. Van Cauter et al., 2000, JAMA.

Objective sleep metrics (HRV recovery scores on wearables) may improve modestly within 2-4 weeks, though no published trial has tested this in athletes using CJC-1295 specifically.

Connective Tissue Subjective Recovery (Weeks 4-8)

Runners with chronic Achilles tendinopathy or patellar tendon soreness often report reduced perceived stiffness by week 6-8. GH and IGF-1 do stimulate tenocyte proliferation and collagen type I synthesis in vitro. Doessing et al., 2010, Journal of Physiology. Whether this translates to measurable tendon stiffness changes in 12 weeks in humans remains untested in an RCT.

Body Composition (Weeks 8-16)

Fat mass reduction and lean mass maintenance during high-volume training are the body composition outcomes most relevant to endurance athletes. Extrapolating from GH deficiency replacement studies, a 12-16 week course might produce 1-2 kg of fat reduction with stable lean mass, though the effect in athletes already at low body fat (<15% in men, <22% in women) is likely smaller than in untrained or GH-deficient populations.

VO2max and Performance (Speculative)

No trial has linked CJC-1295 to improved VO2max. The indirect mechanism (better recovery allowing greater training volume) is plausible but unproven. Athletes should not expect a direct ergogenic effect on aerobic power output.

Adverse Effects and Contraindications

Common Side Effects

• Water retention: GH increases sodium and water reabsorption. Athletes may notice 1-3 lb transient water weight gain in weeks 1-2. It typically resolves as the body adjusts. Reduce dose if joint swelling occurs.
• Injection-site reactions: Redness, itching, or a small nodule at the injection site. Rotating sites and allowing reconstituted peptide to reach room temperature before injection reduces this.
• Vivid dreams or sleep disruption: Reported in roughly 10-20% of users in practitioner case series. Shifting the injection to the morning resolves this in most cases.
• Paresthesias (tingling): A known GH-class effect from fluid shifts around peripheral nerves. Usually mild and self-limiting.

Who Should Not Use CJC-1295

• Active malignancy or personal history of cancer (GH is mitogenic).
• Diabetic patients or pre-diabetes with HbA1c greater than 5.6% without endocrinology co-management.
• Pregnancy or breastfeeding.
• Hypopituitarism managed with prescribed GH therapy (unless co-prescribing clinician is involved).
• Athletes subject to WADA testing: CJC-1295 is prohibited under S2 (Peptide Hormones, Growth Factors, and Related Substances), and no therapeutic use exemption process currently applies to GHRH analogs. WADA Prohibited List 2024.

Regulatory and Sourcing Considerations

CJC-1295 is not FDA-approved for any indication. It is classified as a research compound in the United States. The FDA has issued warning letters to compounding pharmacies supplying CJC-1295 for patient use without appropriate regulatory standing. FDA Compounding Guidance.

Athletes sourcing CJC-1295 outside of a physician-supervised protocol face two risks: product purity and legal exposure. A 2018 analysis of peptide products sold online found that a meaningful proportion contained peptides at concentrations outside the labeled amount or were contaminated with particulates. Physicians ordering through accredited 503A or 503B compounding pharmacies provide the best quality assurance currently available.

The Endocrine Society's Clinical Practice Guideline on GH deficiency explicitly states it does not recommend GH or GH secretagogues for use in healthy adults or athletes. Molitch et al., 2011, Journal of Clinical Endocrinology and Metabolism. Clinicians prescribing CJC-1295 off-label bear responsibility for documenting rationale, obtaining informed consent, and monitoring biochemical parameters.

The Practitioner's Honest Assessment of Evidence Quality

The table below grades each claimed benefit by evidence level.

| Claimed Benefit | Evidence Level | Source | |---|---|---| | Increases GH pulse amplitude | Phase I/II RCT in healthy adults | Jetté et al., 2005 | | Raises IGF-1 for 9-11 days post-injection | Phase I/II RCT | Jetté et al., 2005 | | Improves slow-wave sleep | Mechanistic inference from GH-sleep coupling | Van Cauter et al., 2000 | | Supports connective tissue repair | In vitro + GH replacement extrapolation | Doessing et al., 2010 | | Reduces fat mass | GH deficiency RCT extrapolation | Cochrane, 2018 | | Improves VO2max or performance | No direct evidence; mechanistic speculation only | N/A |

"The use of growth hormone secretagogues in healthy, trained athletes remains outside the scope of current evidence-based guidelines," notes the Endocrine Society's position on GH and sport. Endocrine Society.

A HealthRX supervising physician should confirm IGF-1 targets with each patient individually before the first injection. Targets for endurance athletes typically sit at the 50th-75th percentile of the age-sex-matched reference range, not at supraphysiologic levels.

Practical Checklist Before Starting CJC-1295

1. Confirm no active cancer history or pre-diabetes (<5.6% HbA1c on baseline labs).
2. Draw baseline IGF-1, fasting glucose, HbA1c, cortisol, lipid panel, TSH, and free T4.
3. Obtain CJC-1295 from a licensed 503A/503B compounding pharmacy through a supervising physician.
4. Reconstitute with bacteriostatic water to 1 mg/mL. Store refrigerated.
5. Inject 300 mcg subcutaneously 30-60 minutes before sleep, once weekly for the first 4 weeks.
6. Recheck IGF-1 at week 6-8. If IGF-1 is in the upper normal range, consider increasing to twice weekly or to 500 mcg once weekly.
7. Complete cycle at week 12-16. Draw a full repeat panel.
8. Take 4-8 weeks off before considering the next cycle.
9. Do not use if subject to WADA testing.